<DOC>
	<DOCNO>NCT02057835</DOCNO>
	<brief_summary>BI 691751 currently develop inhibit growth prevent rupture atherosclerotic plaque consequently reduce risk major cardiovascular event patient establish atherosclerotic disease . 1334.5 Pan Asian Phase 1 study investigate safety , tolerability pharmacokinetics BI 691751 healthy Chinese Japanese male volunteer .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Single Rising Oral Doses BI 691751 Healthy Asian Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 . Healthy male base upon complete medical history , include physical examination , vital sign ( blood pressure , pulse rate ) , 12lead ECG , clinical laboratory test 2 . Chinese ethnicity , Japanese ethnicity accord follow criterion : Chinese ; bear China ethnic Chinese born outside China , descendent 4 ethnic Chinese grandparent born China Japanese ; born Japan hold Japanese passport , live outside Japan &lt; 10 year , parent grandparent born Japan 3 . Age within range 20 45 year 4 . Body mass index within range 18.5 25 kg/m2 5 . Signed date write informed consent prior admission study accordance GCP local legislation . Exclusion criterion : 1 . Any finding medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator . Pulse rate outside range 5090 bpm blood pressure outside range 90140 systolic 5090 mmHg diastolic blood pressure confirm repeat measurement . 2 . Any laboratory value outside reference range investigator considers clinical relevance 3 . Any evidence concomitant disease judge clinically relevant investigator 4 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 5 . Surgery gastrointestinal tract could interfere kinetics study drug 6 . Diseases central nervous system ( epilepsy ) , central neurological disorder psychiatric disorder 7 . History relevant orthostatic hypotension , faint spell , blackouts 8 . Relevant chronic acute infection 9 . History relevant allergy/hypersensitivity ( include allergy trial medication excipients ) 10 . Intake drug long halflife ( great 24 hour ) within 30 day less 10 halflives respective drug prior study drug administration 11 . Use drug might reasonably influence result trial might prolong QT/QTc interval within 14 day prior study drug administration 12 . Participation another trial investigational drug administration within 60 day prior administration trial medication 13 . Smoker ( 10 cigarette 3 cigar 3 pipes/day ) 14 . Inability refrain smoke specify trial day 15 . Alcohol abuse ( consumption than30 g/day ) 16 . Drug abuse positive drug screen 17 . Blood donation ( 100 mL within 30 day prior administration trial medication intend trial ) 18 . Intention perform excessive physical activity within one week prior administration trial medication trial 19 . Inability comply dietary regimen trial site 20 . A marked baseline prolongation QT/QTc interval ( repeat demonstration QTc interval great 450 m ) relevant ECG find 21 . A history additional risk factor Torsades de Pointes ( heart failure , hypokalemia , family history Long QT Syndrome ) 22 . Subject assessed investigator unsuitable inclusion , instance , consider able understand comply study requirement , condition would allow safe participation study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>